Skip to search formSkip to main contentSkip to account menu

NPI 2358

Known as: (3Z,6Z)-6-benzylidene-3-{[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylidene}piperazine-2,5-dione, NPI-2358, NPI2358 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
SummaryBackground Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) that destabilizes tumor vascular endothelial cell… 
Highly Cited
2012
Highly Cited
2012
Plinabulin (11, NPI-2358) is a potent microtubule-targeting agent derived from the natural diketopiperazine "phenylahistin" (1… 
Review
2012
Review
2012
Several therapies targeting angiogenesis are currently in development for non-small cell lung cancer (NSCLC). This review… 
2011
2011
Abstract Purpose: This study investigated the anti-tumour effects of the novel vascular disrupting agent plinabulin (NPI-2358… 
Highly Cited
2010
Highly Cited
2010
Purpose: Plinabulin (NPI-2358) is a vascular disrupting agent that elicits tumor vascular endothelial architectural… 
2009
2009
3571 Background: NPI-2358 is a vascular disrupting agent (VDA) that destabilizes tumor vascular endothelial cell architecture… 
Review
2007
Review
2007
  • S. Cai
  • Recent Patents on Anti-Cancer Drug Discovery
  • 2007
  • Corpus ID: 25873315
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
Highly Cited
2006
Highly Cited
2006
The diketopiperazine NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which…